| Environmental Protection: | Yes |
|---|---|
| Color: | White |
| Appearance: | Powder |
| CAS No.: | 2023788-19-2 |
| MOQ: | 1g |
| Stock Condition: | in Stock |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
|
Product Name
|
Tirzepatide |
|
Cas
|
2023788-19-2 |
|
Analysis
|
HPLC
|
|
Storage
|
Keep in a cool and dry place, well-closed, away from moisture or direct sunlight.
|
Tirzepatide is a novel medication that is FDA-approved for the treatment of type 2 diabetes mellitus. Given its potent weight loss properties, tirzepatide be used off-label for obesity treatment. It works as a dual GLP-1 agonist and GIP agonist to maximize similar benefits that are seen with GLP-1 medications such as semaglutide. It is currently implemented as a second-line diabetes medication, similar to GLP-1 medications, and given as a once-a-week subcutaneous injectable. The FDA approved Tirzepatide in May 2022.
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, which is FDA-approved for treating type 2 diabetes mellitus. It is important to note that tirzepatide is not approved for treating type-1 diabetes mellitus and has not been studied in patients with pancreatitis. Tirzepatide is a GIP receptor and GLP-1 receptor agonist, leading to significantly improved glycemic control in type 2 diabetics and significant weight reduction.[1]
The FDA approved Tirzepatide in May 2022. Tirzepatide can also be used off-label for treating obesity. It is currently implemented as a second-line diabetes medication, similar to GLP-1 medications like semaglutide.[2] It is a once-a-week subcutaneous injectable medication with incremental dose increases.
| Semaglutide | Vial package | 5mg 10mg 15mg |
| Tirzepatide | Vial package | 5mg 10mg 15mg |
| Retatrutide | Vial package | 5mg 10mg 15mg |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}